Ascendis Pharma A
corporate_fare Company Profile
Ascendis Pharma A (NASDAQ:ASND) is a publicly traded company in the Life Sciences sector. Wiseek monitors ASND SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.
Recent high-impact activity:
- TransCon PTH Shows Sustained Efficacy, Safety Through 3.5 Years in Phase 3 Hypoparathyroidism Trial
- Long-Term Data: TransCon PTH Sustains Efficacy for 5 Years in Hypoparathyroidism
- EVP Sells All Direct Holdings for $4.6M Amidst Positive Company News
- Ascendis Pharma Reports Strong Q1 Profit & $187.5M PRV Sale; Redeems $575M Convertible Notes
- Pivotal Trial Shows TransCon CNP Delivers Sustained 2-Year Growth Gains in Achondroplasia
Financial Snapshot
Insider Transactions
ASND files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.